Updated July 2026 · 8 min read

Terlipressin (Terlivaz): The ICU Nurse's Guide

Part of the ICU Emergencies Hub — browse every related guide in one place.

For years American ICU nurses treated hepatorenal syndrome with off-label norepinephrine or midodrine-octreotide because the purpose-built drug wasn't approved here. Terlipressin changed that — it's the first agent FDA-approved specifically to improve kidney function in hepatorenal syndrome. It's powerful, it's targeted, and it carries some of the most serious black-box warnings you'll manage. Knowing how it works and what it can do is increasingly core critical-care knowledge.

The problem it solves: why the kidneys fail in liver failure

Hepatorenal syndrome is kidney failure caused by circulatory chaos, not by structurally damaged kidneys. In advanced cirrhosis, the splanchnic (gut) circulation dilates massively. That steals effective blood volume away from the rest of the body; the kidneys sense underperfusion and clamp down, and glomerular filtration collapses even though the kidneys themselves are structurally normal. More IV fluid doesn't fix it — the problem is where the blood is pooling. This is the same physiology covered in the hepatorenal syndrome overview.

Terlipressin attacks the root cause: as a V1 receptor agonist, it constricts that dilated splanchnic bed, pushing effective blood volume back into the central circulation and restoring perfusion pressure to the kidney. Function can recover enough to buy time toward liver transplant or recovery.

How it's given — and why albumin comes with it

The albumin pairing matters: terlipressin squeezes the leaky, dilated circulation while albumin fills it, and together they restore the effective blood volume the kidney needs. Nurses track the creatinine trend as the marker of response — a falling creatinine means it's working; a flat creatinine after a defined trial means it isn't, and the drug is stopped.

The warnings that define bedside monitoring

Serious respiratory failure. Terlipressin carries a boxed warning for respiratory failure, which can be fatal. Patients with significant hypoxia or acute-on-chronic liver failure at the severe end are at particularly high risk. Volume status is central — giving terlipressin to an already fluid-overloaded, hypoxic patient is dangerous, which is why oxygenation and volume are assessed before and during therapy. Rising oxygen requirement, new dyspnea, or crackles on a terlipressin patient is an urgent finding.

Ischemic complications. Because it's a potent vasoconstrictor, terlipressin can compromise perfusion the same way vasopressin can. Watch for peripheral/digital ischemia (dusky, mottled, cold fingers and toes), mesenteric ischemia (new abdominal pain, rising lactate), and cardiac ischemia (chest pain, arrhythmia, ECG changes). Assess distal perfusion each shift.

Fluid overload. Combined with the albumin load, terlipressin can tip patients into volume overload — another route to the respiratory failure it's warned for. Daily weights, intake/output, and lung assessment are the monitoring backbone.

Terlipressin vs. the old workarounds

Before its approval, HRS was treated with norepinephrine (in the ICU, titrated on a pump) or midodrine plus octreotide (on the floor). Terlipressin's advantage is that it's purpose-built and studied specifically for HRS, and it can be used outside a norepinephrine-capable ICU setting. Its disadvantage is the boxed respiratory-failure risk and cost. Which agent a patient gets depends on their oxygenation, how sick they are, and local practice — so you'll still see all three approaches.

Bottom line

Terlipressin is the first drug approved in the U.S. to reverse the kidney failure of hepatorenal syndrome, and it works by fixing the circulation rather than the kidney — constricting the dilated splanchnic bed, paired with albumin, to restore renal perfusion. Track the creatinine as the response marker, and treat the boxed warnings as your monitoring priorities: watch the lungs for respiratory failure, watch the extremities and gut for ischemia, and watch the volume status. Understand that patient selection is itself a safety decision, and you'll manage this powerful drug the way it demands.

This article is general educational information for licensed clinicians and students, not medical advice or a substitute for your institution's protocols, pharmacy guidance, or a provider's orders. Always follow facility policy and verify doses independently.